Synteka Bio신테카바이오

Synteka Bio's shares have fallen sharply over the past year while the company keeps reporting large operating losses against small revenue.

Synteka Bio is a Korean AI drug discovery company with trailing twelve-month revenue of ₩3.1B against an operating loss of ₩10.5B as of H1 2026. The share price is ₩1,105 on 2026-10-27, down 66.4% over one year, with a market capitalisation of about ₩26.8B. Trailing free cash flow was negative ₩10.8B, and the company holds ₩7.5B in cash against ₩6.4B in borrowings.

What stands out

• Revenue jumped from about ₩121M in 2024 to ₩3.4B in 2025, but operating losses stayed above ₩10B in each recent year.
• Net loss in 2025 was ₩17.4B, larger than the operating loss, and trailing net margin is about -389%.
• Cash of ₩7.5B exceeds borrowings of ₩6.4B, though free cash flow is strongly negative.
• Price-to-book is about 1.0 and price-to-sales about 8.7; earnings-based ratios are not available because the company is loss-making.
• Recent filings include an extraordinary shareholders' meeting, a notice on stock purchase options, a change of largest shareholder, and a material matters report on early acquisition of own convertible bonds.
• Foreign ownership fell from 0.2% to 0% over 60 days, and 20-day foreign flows were net negative.

What to watch

• Outcomes of the extraordinary shareholders' meeting and the stock purchase option grant, which could dilute existing holders.
• Whether the company's planned management innovation committee and internal control changes, reported in news on 2026-10-21, are followed by further filings.
• Next periodic financial filings, to see whether revenue growth continues and whether the operating loss narrows or the cash position changes.